SCHEMBL2857002

SCHEMBL2857002

CC(C)(C)OC(=O)N1C[C@@H](N2CCN(c3cc(C(F)(F)F)nc4ccc(OC(F)(F)F)cc34)CC2)C[C@H]1C(=O)N1CCSC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 13/20 0.52
DPP8 Q6V1X1 1/20 0.52
DPP9 Q86TI2 1/20 0.52
ADRB2 P07550 3/20 0.35
PREP P48147 1/20 0.34
ABHD6 Q9BV23 2/20 0.33
MAPT P10636 1/20 0.33
DAGLA Q9Y4D2 1/20 0.33
ADRA2A P08913 1/20 0.33
HTR2C P28335 1/20 0.33
AXL P30530 1/20 0.33
HRH1 P35367 1/20 0.33
HTR2B P41595 1/20 0.33
HTR6 P50406 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2712185 0.94 DPP4 (0.53) DPP4DPP8DPP9ADRB2PREP
SCHEMBL2711657 0.91 DPP4 (0.54) DPP4DPP8DPP9ADRB2PREP
SCHEMBL2711588 0.90 DPP4 (0.54) DPP4DPP8DPP9ADRB2MAPT
SCHEMBL2709325 0.89 DPP4 (0.65) DPP4DPP8DPP9ADRB2MAPT
SCHEMBL2708833 0.89 DPP4 (0.65) DPP4DPP8DPP9ADRB2MAPT
SCHEMBL2710367 0.88 DPP4 (0.53) DPP4DPP8DPP9PREPMAPT
SCHEMBL2726626 0.87 DPP4 (0.62) DPP4DPP8DPP9ADRB2MAPT
SCHEMBL2856739 0.86 DPP4 (0.50) DPP4DPP8DPP9
SCHEMBL2709330 0.84 DPP4 (0.52) DPP4DPP8DPP9PREP
SCHEMBL2862062 0.84 DPP4 (0.47) DPP4DPP8DPP9PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 DPP4 1/4885DPP8 5/4885DPP9 4/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 DPP4 1/4885DPP8 5/4885DPP9 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.